CHICAGO — In patients with stage IVB anaplastic thyroid cancer, the inclusion of adjuvant pembrolizumab to conventional multimodal therapy shows significant benefits in reducing the recurrence ...

In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received pembrolizumab developed immune-related adverse events — findings that ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Dr. Shannon Westin (Host), Dr. Brian Slomovitz (Guest) Dr. Shannon Westin and her guest, Dr. Brian Slomovitz discuss the article “Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without ...

At a median follow-up of 29.9 months (range, 12.8-43.0), significant differences in overall survival (OS) were observed between the pembrolizumab plus chemoradiotherapy group and the chemoradiotherapy ...

Design We correlated the prognostic outcomes of HCC patients from a pembrolizumab trial (NCT03419481) with tumourous cell expressions of all HDAC isoforms by single-cell RNA sequencing. We ...

As a second-line treatment, the patient received pembrolizumab, an ICI that targets programmed death-1 (PD-1), a checkpoint located on immune cells. After three treatment cycles, the patient ...

Currently, several combination regimens have been approved, including atezolizumab plus bevacizumab, pembrolizumab plus lenvatinib, camrelizumab plus apatinib, and sintilimab plus bevacizumab ...